| Business Summary | | Cubist
Pharmaceuticals,
Inc.
is
a
specialty
pharmaceutical
company
focused
on
the
research,
development
and
commercialization
of
novel
antimicrobial
drugs
to
combat
serious
and
life-threatening
bacterial
and
fungal
infections.
Cidecin
(daptomycin
for
injection),
the
Company's
lead
product
candidate
and
the
first
in
a
new
class
of
antimicrobial
drug
candidates,
called
lipopeptides,
has
demonstrated
the
ability,
in
vitro,
to
rapidly
kill
virtually
all
clinically
significant
Gram-positive
bacteria,
including
those
that
have
become
resistant
to
current
therapies.
The
Company
expanded
its
product
pipeline
by
announcing
the
development
of
an
oral
formulation
of
daptomycin,
and
by
acquiring
the
worldwide
rights
to
research,
develop,
manufacture
and
sell
oral
ceftriaxone,
an
orally
active
version
of
Rocephin,
which
is
an
intravenous
antibiotic.
Each
of
these
programs
is
in
the
pre-clinical
stage
of
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Cubist
Pharmaceuticals
is
a
specialty
pharmaceutical
company
focused
on
the
research,
development
and
commercialization
of
new
antimicrobial
drugs
to
combat
serious
and
life-threatening
bacterial
and
fungal
infections.
For
the
six
months
ended
6/30/01,
revenues
rose
95%
to
$5.7
million.
Net
loss
rose
96%
to
$34.4
million.
Results
reflect
increased
amounts
earned
under
collaborative
agreements,
offset
by
costs
related
to
the
expanded
development
of
Cidecin. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Scott Rocklage, Ph.D., 46 Chairman,
CEO | $331K | Thomas Shea, 41 CFO,
Chief Accounting Officer, VP of Fin. and Admin., Tre | -- | Julian Davies, Ph.D., 69 Exec.
VP, Technology Devel. | -- | Francis Tally, M.D., 60 Exec.
VP-Scientific Affairs | 291K | Robert McCormack, Ph.D., 47 Sr.
VP, Drug Devel. | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|